Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OCEAN study of osimertinib for radiation-naive brain metastases in EGFR-mutated non-small cell lung cancer
jRCTs071180017Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Dec 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of osimertinib in non-small cell lung cancer (NSCLC) (2 cohorts), sponsored by AstraZeneca. Primary endpoint: Overall response rate of metastatic brain tumor. Started Dec 2016; status: completed.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on jRCTs071180017.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs071180017.